Patents by Inventor Thue Johansen

Thue Johansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications
    Patent number: 11673933
    Abstract: The present invention relates to insulin degludec for use in medicine.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: June 13, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Per Knud Christensen, Thue Johansen, Simon Skibsted, Kajsa Kvist
  • DOSING REGIMEN
    Publication number: 20220152160
    Abstract: The present invention relates to a long acting insulin analogue for use in reducing the risk of hypoglycaemia in a patient suffering from diabetes and requiring high amounts of delivered insulin, wherein the long acting insulin analogue is administered to said patient and in an amount of greater than 80 U/administration.
    Type: Application
    Filed: December 16, 2021
    Publication date: May 19, 2022
    Inventor: Thue Johansen
  • INSULIN DEGLUDEC FOR IMPROVEMENT OF GLYCAEMIC CONTROL AND REDUCTION OF ACUTE AND LONG-TERM DIABETES COMPLICATIONS
    Publication number: 20200181222
    Abstract: The present invention relates to insulin degludec for use in medicine.
    Type: Application
    Filed: November 28, 2017
    Publication date: June 11, 2020
    Inventors: Per Knud Christensen, Thue Johansen, Simon Skibsted, Kajsa Kvist
  • Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
    Patent number: 10596229
    Abstract: The present invention relates to methods for treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof, effective dosages of an insulin, insulin analogue or derivative thereof, which exhibits a prolonged profile of action, wherein said dosages are administered at intervals of varying length.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: March 24, 2020
    Assignee: Novo Nordisk A/S
    Inventor: Thue Johansen
  • DOSING REGIMEN
    Publication number: 20190160155
    Abstract: The present invention relates to a long acting insulin analogue for use in reducing the risk of hypoglycaemia in a patient suffering from diabetes and requiring high amounts of delivered insulin, wherein the long acting insulin analogue is administered to said patient and in an amount of greater than 80 U/administration.
    Type: Application
    Filed: January 30, 2019
    Publication date: May 30, 2019
    Inventor: Thue Johansen
  • Administration regime
    Patent number: 10137172
    Abstract: The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit, as well as to kits for use in the same. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin comprises or consists of the following steps: (a) optionally providing a blood sample to be tested from an individual in need of treatment; (b) taking a single fasting blood (or plasma) glucose measurement from said individual in need of treatment; (c) using the single fasting blood (or plasma) glucose measurement to determine the insulin dose to be administered; and (d) administering the long-acting or ultra-long insulin to the individual at the dose determined in step (c).
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: November 27, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Thue Johansen, Ann Marie Ocampo Francisco, Torsten Christensen, Jens Harald Kongsoe, Trine Ahlgreen
  • Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
    Publication number: 20180125946
    Abstract: The present invention relates to methods for treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof, effective dosages of an insulin, insulin analogue or derivative thereof, which exhibits a prolonged profile of action, wherein said dosages are administered at intervals of varying length.
    Type: Application
    Filed: November 13, 2017
    Publication date: May 10, 2018
    Inventor: Thue Johansen
  • Method of treating diabetes mellitus
    Patent number: 9884094
    Abstract: A combination comprising at least a first insulin-like compound and a second insulin-like compound for treating a condition or a disease in a subject in need thereof where administration of insulin would be of benefit to said subject is described.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: February 6, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Thue Johansen, Henriette Mersebach, Mads Axelsen, Martin Lange
  • DOSING REGIMEN
    Publication number: 20170319664
    Abstract: The present invention relates to a long acting insulin analogue for use in reducing the risk of hypoglycaemia in a patient suffering from diabetes and requiring high amounts of delivered insulin, wherein the long acting insulin analogue is administered to said patient and in an amount of greater than 80 U/administration.
    Type: Application
    Filed: May 22, 2017
    Publication date: November 9, 2017
    Inventor: Thue Johansen
  • Treating diabetes melitus using insulin injections with less than daily injection frequency
    Patent number: 9603904
    Abstract: The present invention relates to an insulin derivative for the treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof, effective dosages of the insulin derivative, wherein said insulin derivative exhibits a prolonged profile of action and wherein said dosages are administered at intervals longer than 24 hours.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: March 28, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Thue Johansen, Birgitte Koch Michelsen, Berit Edsberg
  • Dosing Regimen
    Publication number: 20160296602
    Abstract: The present invention relates to a long acting insulin analogue for use in reducing the risk of hypoglycaemia in a patient suffering from diabetes and requiring high amounts of delivered insulin, wherein the long acting insulin analogue is administered to said patient and in an amount of greater than 80 U/administration.
    Type: Application
    Filed: March 19, 2014
    Publication date: October 13, 2016
    Inventor: Thue Johansen
  • Novel Administration Regime
    Publication number: 20160058840
    Abstract: The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit, as well as to kits for use in the same. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin comprises or consists of the following steps: (a) optionally providing a blood sample to be tested from an individual in need of treatment; (b) taking a single fasting blood (or plasma) glucose measurement from said individual in need of treatment; (c) using the single fasting blood (or plasma) glucose measurement to determine the insulin dose to be administered; and (d) administering the long-acting or ultra-long insulin to the individual at the dose determined in step (c).
    Type: Application
    Filed: April 30, 2014
    Publication date: March 3, 2016
    Inventors: Thue Johansen, Ann Marie Ocampo Francisco, Torsten Christensen, Jens Harald Kongsoe, Trine Ahlgreen
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20150126439
    Abstract: A combination comprising at least a first insulin-like compound and a second insulin-like compound for treating a condition or a disease in a subject in need thereof where administration of insulin would be of benefit to said subject is described.
    Type: Application
    Filed: May 1, 2013
    Publication date: May 7, 2015
    Inventors: Thue Johansen, Henriette Mersebach, Mads Axelsen, Martin Lange
  • Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
    Publication number: 20130261051
    Abstract: The present invention relates to methods for treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof, effective dosages of an insulin, insulin analogue or derivative thereof, which exhibits a prolonged profile of action, wherein said dosages are administered at intervals of varying length.
    Type: Application
    Filed: October 27, 2011
    Publication date: October 3, 2013
    Inventor: Thue Johansen
  • TREATING DIABETES MELITUS USING INSULIN INJECTIONS WITH LESS THAN DAILY INJECTION FREQUENCY
    Publication number: 20110230402
    Abstract: The present invention relates to an insulin derivative for the treatment of a condition or disease where administration of insulin will be of benefit, comprising administering, to a patient in need thereof, effective dosages of the insulin derivative, wherein said insulin derivative exhibits a prolonged profile of action and wherein said dosages are administered at intervals longer than 24 hours.
    Type: Application
    Filed: October 29, 2009
    Publication date: September 22, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Thue Johansen, Birgitte Koch Michelsen, Berit Edsberg
  • Prevention of hyperinsulinemia in subjects undergoing growth hormone (GH) treatment
    Patent number: 7141548
    Abstract: The present invention provides methods and compositions for preventing hyperinsulinemia that can result from therapeutic administration of growth hormone. The methods are carried out by imposing a restricted high-fat diet and/or by administering one or more drugs that lower serum lipids.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: November 28, 2006
    Assignee: Novo Nordisk A/S
    Inventors: Thue Johansen, Kjell Malmlof
  • Prevention of hyperinsulinemia in subjects undergoing growth hormone (GH) treatment
    Publication number: 20050004023
    Abstract: The present invention provides methods and compositions for preventing hyperinsulinemia that can result from therapeutic administration of growth hormone. The methods are carried out by imposing a restricted high-fat diet and/or by administering one or more drugs that lower serum lipids.
    Type: Application
    Filed: April 9, 2004
    Publication date: January 6, 2005
    Inventors: Thue Johansen, Kjell Malmlof
  • Prevention of hyperinsulinemia in subjects undergoing growth hormone (GH) treratment
    Publication number: 20040220109
    Abstract: The present invention provides methods and compositions for preventing hyperinsulinemia that can result from therapeutic administration of growth hormone. The methods are carried out by imposing a restricted high-fat diet and/or by administering one or more drugs that lower serum lipids.
    Type: Application
    Filed: June 4, 2004
    Publication date: November 4, 2004
    Inventors: Thue Johansen, Kjell Malmlof